Standout Papers

<i>IDH1</i>and<i>IDH2</i>Mutations in Gliomas 1996 2026 2006 2016 4.2k
  1. IDH1andIDH2Mutations in Gliomas (2009)
    Hai Yan, D. Williams Parsons et al. New England Journal of Medicine
  2. Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme (2007)
    James J. Vredenburgh, Annick Desjardins et al. Journal of Clinical Oncology
  3. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma (2007)
    James J. Vredenburgh, Annick Desjardins et al. Clinical Cancer Research
  4. Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial (1996)
    R O Dillman, James E. Herndon et al. JNCI Journal of the National Cancer Institute
  5. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups (2008)
    Gary M. Strauss, James E. Herndon et al. Journal of Clinical Oncology
  6. Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma (2010)
    John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology
  7. Recurrent Glioblastoma Treated with Recombinant Poliovirus (2018)
    Annick Desjardins, Matthias Gromeier et al. New England Journal of Medicine
  8. Phase II Trial of Gefitinib in Recurrent Glioblastoma (2003)
    Jeremy N. Rich, David A. Reardon et al. Journal of Clinical Oncology
  9. Video-Assisted Thoracic Surgery Lobectomy: Report of CALGB 39802—A Prospective, Multi-Institution Feasibility Study (2007)
    Steven Swanson, James E. Herndon et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 39 from Science/Nature 128 standout
Sub-graph 1 of 21

Citing Papers

Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
2024 Standout
Fibroblasts in cancer: Unity in heterogeneity
2023 Standout
6 intermediate papers

Works of James E. Herndon being referenced

A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
2008
Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results
2005
and 5 more

Author Peers

Author Last Decade Papers Cites
James E. Herndon 14922 13208 11233 477 36.7k
Elizabeth A. Eisenhauer 12565 15013 12331 205 41.1k
Kenneth R. Hess 14542 15103 8378 506 40.9k
Patrick Y. Wen 11228 9683 23253 775 41.8k
Jill S. Barnholtz‐Sloan 9065 6891 18897 433 39.7k
Alba A. Brandes 9461 6491 23019 356 33.2k
Henry S. Friedman 7759 8859 21140 564 37.6k
Mark R. Gilbert 6592 5722 14723 482 24.1k
Roger Stupp 13661 9311 30511 373 48.5k
Michael D. Prados 7284 4843 18387 407 27.0k
Janet Dancey 15054 19412 2719 202 37.3k

All Works

Loading papers...

Rankless by CCL
2026